株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ウェゲナー肉芽腫症:世界の治験レビュー

Wegener's Granulomatosis Global Clinical Trials Review, H2, 2014

発行 GlobalData 商品コード 318812
出版日 ページ情報 英文 78 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
ウェゲナー肉芽腫症:世界の治験レビュー Wegener's Granulomatosis Global Clinical Trials Review, H2, 2014
出版日: 2014年10月31日 ページ情報: 英文 78 Pages
概要

当レポートでは、ウェゲナー肉芽腫症の臨床試験に関連する基本情報やデータを提供しており、試験件数および被験者の募集状況、段階別の動向、臨床試験を実施している主な製薬企業および研究機関のプロファイルなどを提供しています。

イントロダクション

  • ウェゲナー肉芽腫症
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中南米の主要国における治験件数

G7諸国での治験件数:免疫疾患治療薬の治験におけるウェゲナー肉芽腫症の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:免疫疾患治療薬の治験におけるウェゲナー肉芽腫症の割合

E7諸国における段階別の治験件数

E7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

未完了の治験件数

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

ウェゲナー肉芽腫症治療薬の治験に携わっている主要企業

有望な薬剤

治験のプロファイル

  • 主要企業の治験の概要
    • F. Hoffmann-La Roche Ltd.
    • Nippon Kayaku Co., Ltd.
    • Zenyaku Kogyo Co., Ltd.
    • Nordic Pharma Group
    • Human Genome Sciences, Inc. (Inactive)
    • Anthera Pharmaceuticals, Inc.
  • 代表的な研究機関・病院の治験の概要
    • The National Institute of Allergy and Infectious Diseases
    • Assistance Publique - Hopitaux de Paris
    • University of Pennsylvania
    • Cambridge University Hospitals NHS Foundation Trust
    • University of Oxford
    • National Cancer Institute
    • University Medical Center Groningen
    • University Hospitals Birmingham NHS Foundation Trust
    • Northwestern University
    • Children's Hospital of Eastern Ontario

5つの代表的な治験のプロファイル

付録

目次
Product Code: GDHC2413CTIDB

GlobalData's clinical trial report, "Wegener's Granulomatosis Global Clinical Trials Review, H2, 2014" provides data on the Wegener's Granulomatosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Wegener's Granulomatosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Wegener's Granulomatosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Wegener's Granulomatosis
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Wegener's Granulomatosis to Immunology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Wegener's Granulomatosis to Immunology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Wegener's Granulomatosis
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Wegener's Granulomatosis Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • F. Hoffmann-La Roche Ltd.
      • Clinical Trial Overview of F. Hoffmann-La Roche Ltd.
      • Nippon Kayaku Co., Ltd.
      • Clinical Trial Overview of Nippon Kayaku Co., Ltd.
      • Zenyaku Kogyo Co., Ltd.
      • Clinical Trial Overview of Zenyaku Kogyo Co., Ltd.
      • Nordic Pharma Group
      • Clinical Trial Overview of Nordic Pharma Group
      • Human Genome Sciences, Inc. (Inactive)
      • Clinical Trial Overview of Human Genome Sciences, Inc. (Inactive)
      • Anthera Pharmaceuticals, Inc.
      • Clinical Trial Overview of Anthera Pharmaceuticals, Inc.
    • Clinical Trial Overview of Top Institutes / Government
      • The National Institute of Allergy and Infectious Diseases
      • Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases
      • Assistance Publique - Hopitaux de Paris
      • Clinical Trial Overview of Assistance Publique - Hopitaux de Paris
      • University of Pennsylvania
      • Clinical Trial Overview of University of Pennsylvania
      • Cambridge University Hospitals NHS Foundation Trust
      • Clinical Trial Overview of Cambridge University Hospitals NHS Foundation Trust
      • University of Oxford
      • Clinical Trial Overview of University of Oxford
      • National Cancer Institute
      • Clinical Trial Overview of National Cancer Institute
      • University Medical Center Groningen
      • Clinical Trial Overview of University Medical Center Groningen
      • University Hospitals Birmingham NHS Foundation Trust
      • Clinical Trial Overview of University Hospitals Birmingham NHS Foundation Trust
      • Northwestern University
      • Clinical Trial Overview of Northwestern University
      • Children's Hospital of Eastern Ontario
      • Clinical Trial Overview of Children's Hospital of Eastern Ontario
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Wegener's Granulomatosis Therapeutics, Global, Clinical Trials by Region, 2014*
  • Wegener's Granulomatosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Wegener's Granulomatosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2014*
  • Proportion of Wegener's Granulomatosis to Immunology Clinical Trials, G7 Countries (%), 2014*
  • Wegener's Granulomatosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Wegener's Granulomatosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Wegener's Granulomatosis to Immunology Clinical Trials, E7 Countries (%), 2014*
  • Wegener's Granulomatosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Wegener's Granulomatosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Wegener's Granulomatosis Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Wegener's Granulomatosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Wegener's Granulomatosis Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Wegener's Granulomatosis Therapeutics, Global, Suspended Clinical Trials, 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Wegener's Granulomatosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Nippon Kayaku Co., Ltd., 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Zenyaku Kogyo Co., Ltd., 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Nordic Pharma Group, 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Human Genome Sciences, Inc. (Inactive), 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Anthera Pharmaceuticals, Inc., 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Allergy and Infectious Diseases, 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pennsylvania, 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Cambridge University Hospitals NHS Foundation Trust, 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Oxford, 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University Medical Center Groningen, 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospitals Birmingham NHS Foundation Trust, 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Northwestern University, 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Hospital of Eastern Ontario, 2014*

List of Figures

  • Wegener's Granulomatosis Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Wegener's Granulomatosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Wegener's Granulomatosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014*
  • Proportion of Wegener's Granulomatosis to Immunology Clinical Trials, G7 Countries (%), 2014*
  • Wegener's Granulomatosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Wegener's Granulomatosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Wegener's Granulomatosis to Immunology Clinical Trials, E7 Countries (%), 2014*
  • Wegener's Granulomatosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Wegener's Granulomatosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Wegener's Granulomatosis Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Wegener's Granulomatosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Wegener's Granulomatosis Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Wegener's Granulomatosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Wegener's Granulomatosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top